Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL

BJU International

Volumn 101, Issue 10, 2008, Pages 1223-1226

  Pelzer, Alexandre E ^a   Colleselli, Daniela ^a   Bektic, Jasmin ^a   Schaefer, Georg ^a   Ongarello, Stefano ^b   Schwentner, Christian ^a   Aigner, Fritz ^a   Mitterberger, Michael ^a   Steiner, Eberhard ^a   Bartsch, Georg ^a   Horninger, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Over diagnosis; Prostate cancer; Prostate specific antigen; Screening; Under diagnosis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CHI SQUARE TEST; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AUSTRIA; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION;

EID: 42249115485     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07367.x     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66
2. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993 270 : 948 54
3. Pelzer A, Bektic J, Berger AP et al. Prostate cancer detection in men with prostate specific antigen 4-10 ng/mL using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005 173 : 1926 9
4. Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995 75 : 347 53
5. Pelzer AE, Bektic J, Akkad T et al. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2-10 ng/mL. J Urol 2007 178 : 93 7
6. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002 94 : 981 90
7. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998 159 : 1368 72
8. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003 95 : 868 78
9. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001 28 : 555 65
10. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
11. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002 168 : 525 9
12. Graif T, Loeb S, Roehl KA et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007 178 : 88 92
13. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 271 : 368 74
14. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000 21 (Suppl. 251S 72S
15. de Koning HJ, Auvinen A, Berenguer Sanchez A et al. Large-scale randomized prostate cancer screening trials. program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002 97 : 237 44
16. de Koning HJ, Liem MK, Baan CA et al. Prostate cancer mortality reduction by screening. power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002 98 : 268 73
17. Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA. Biochemical failure in men following radical retropubic prostatectomy. impact of surgical margin status and location. J Urol 2004 172 : 129 32
18. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994 152 : 1714 20
19. Krumholtz JS, Carvalhal GF, Ramos CG et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002 60 : 469 73